Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for depression and neurological disorders. The licensing agreement gives Biogen ...

The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

Eli Lilly has thinned its pipeline in two critical therapeutic areas, axing clinical-phase Alzheimer’s disease and obesity ... Lilly was removing another tau drug candidate, zagotenemab, from ...

Cancer is well represented in the Astellas Pharma portfolio and pipeline, but the drugmaker ... the Tokyo-based company is focused neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi ...